The role of cytokines in pediatric hematologic malignancies: mechanisms of tumor progression and therapeutic implications - a narrative review.

Cytokines play a pivotal role in the progression and pathogenesis of pediatric hematologic malignancies, such as leukemia and lymphoma, by orchestrating the tumor microenvironment (TME). These soluble signaling molecules regulate key processes, including immune modulation, tumor cell proliferation, angiogenesis, and resistance to therapy. Elevated levels of pro-inflammatory cytokines such as interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-α) promote survival pathways, chemoresistance, and immune evasion, while anti-inflammatory cytokines like IL-10 further suppress effective anti-tumor immunity. Targeting cytokine signaling pathways has emerged as a promising therapeutic strategy. Advances in monoclonal antibody therapies, signal transduction inhibitors, and cytokine-neutralizing agents aim to disrupt the pro-tumorigenic effects of cytokines within the TME. Additionally, integrating cytokine modulation with immune checkpoint inhibitors and adoptive cell therapy enhances anti-tumor immune responses. These approaches are complemented by novel therapeutics designed to mitigate resistance to conventional treatments, such as chemotherapies, which are often driven by persistent cytokine-mediated signaling.